Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of HCP1401 vs Co-administration of HCP0605 and HGP1405 in Healthy Males
NCT04252872Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Aug 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Amosartan Plus in hypertension (HTN) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Area Under the Curve to the last measurable concentration at 144 hours and Maximum Plasma Concentration at 144 hours. Started Aug 2015; status: completed.
02
Drugs
Amosartan Plus
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04252872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04252872.